Kodiak, Biomarin and Argenx prepare for clinical catalysts.
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.